Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma

[1]  A. Takano,et al.  Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer , 2021, JAMA network open.

[2]  Samuel H. Wilson,et al.  Genomic and evolutionary classification of lung cancer in never smokers , 2021, Nature Genetics.

[3]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[4]  M. Okada,et al.  Prognostic impact of targetable genetic variants in resected adenocarcinoma of the lung: a narrative review and model proposal for precise evaluation , 2020 .

[5]  S. Toyooka,et al.  Multiplex gene‐panel testing for lung cancer patients , 2020, Pathology international.

[6]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[7]  E. Miyaoka,et al.  Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases. , 2020, The Annals of thoracic surgery.

[8]  Haiquan Chen,et al.  Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. , 2020, The Journal of thoracic and cardiovascular surgery.

[9]  A. Nicholson,et al.  A Grading system for invasive pulmonary adenocarcinoma: a proposal from the IASLC pathology committee. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Haiquan Chen,et al.  The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. , 2020, The Journal of thoracic and cardiovascular surgery.

[11]  M. Okada,et al.  Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. , 2020, Lung cancer.

[12]  Y. Takeshima,et al.  Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma , 2019, Journal of Cancer Research and Clinical Oncology.

[13]  Y. Takeshima,et al.  Increased risk of recurrence in resected EGFR‐positive pN0M0 invasive lung adenocarcinoma , 2018, Thoracic cancer.

[14]  Ramón Rami-Porta,et al.  Lung cancer staging: a concise update , 2018, European Respiratory Journal.

[15]  Kenji Suzuki,et al.  Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma , 2017, The Journal of thoracic and cardiovascular surgery.

[16]  S. Shiono,et al.  The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  M. Okada,et al.  Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma† , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  Kunio Araki,et al.  Prognostic Significance of Solid and Micropapillary Components in Invasive Lung Adenocarcinomas Measuring ≤3 cm. , 2016, Anticancer research.

[19]  Y. Ichinose,et al.  Mutations of the EGFR, K-ras, EML4–ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma , 2016, Surgery Today.

[20]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Fergus Gleeson,et al.  The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Y. Ichinose,et al.  Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  C. Kang,et al.  Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[25]  A. Iafrate,et al.  The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Y. Takeshima,et al.  Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications. , 2014, Lung cancer.

[27]  Y. Ichinose,et al.  The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance , 2014, Surgery Today.

[28]  Jie Yang,et al.  Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. , 2013, Lung cancer.

[29]  M. Ladanyi,et al.  KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma , 2013, Modern Pathology.

[30]  A. Yoshizawa,et al.  Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  P. Laurent-Puig,et al.  Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation , 2006, The American journal of surgical pathology.

[33]  Huqun,et al.  Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. , 2005, Cancer research.

[34]  M. Sonobe,et al.  Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma , 2005, British Journal of Cancer.

[35]  OUP accepted manuscript , 2022, Interactive Cardiovascular and Thoracic Surgery.

[36]  OUP accepted manuscript , 2021, European Journal of Cardio-Thoracic Surgery.

[37]  藤倉雄二,et al.  わが国における成人市中肺炎原因微生物についてのsystematic review/meta‐analysis , 2016 .

[38]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[39]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..